Akcea Therapeutics, Inc. (AKCA)
(Delayed Data from NSDQ)
$26.01 USD
+0.60 (2.36%)
Updated May 3, 2019 04:00 PM ET
After-Market: $26.05 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.01 USD
+0.60 (2.36%)
Updated May 3, 2019 04:00 PM ET
After-Market: $26.05 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Epizyme Gets FDA Nod for Tazverik sNDA in Follicular Lymphoma
by Zacks Equity Research
The FDA grants approval to Epizyme's (EPZM) sNDA for lead drug,Tazverik, for two distinct follicular lymphoma indications.
Ultragenyx Gets FDA Nod for Label Expansion of Crysvita
by Zacks Equity Research
Ultragenyx (RARE) gets FDA approval for the label expansion of Crysvita into tumor-induced osteomalacia.
Editas (EDIT) in Focus: Stock Moves 8.6% Higher
by Zacks Equity Research
Editas (EDIT) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Alnylam???s Share Price Rises YTD on Pipeline Developments
by Zacks Equity Research
Alnylam's (ALNY) share price rises more than 14% year to date based on pipeline developments.
SpringWorks Therapeutics (SWTX) in Focus: Stock Moves 5.9% Higher
by Zacks Equity Research
SpringWorks Therapeutics (SWTX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
ACADIA Files sNDA for Nuplazid in Dementia-Related Psychosis
by Zacks Equity Research
ACADIA (ACAD) files an sNDA for Nuplazid's potential second indication to treat hallucinations and delusions linked to dementia-related psychosis.
Affimed (AFMD) Catches Eye: Stock Jumps 7.2%
by Zacks Equity Research
Affimed (AFMD) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
bluebird Reports New Data on Betibeglogene Autotemcel for TDT
by Zacks Equity Research
bluebird (BLUE) reports new phase III data on betibeglogene autotemcel in TDT.
NeuBase (NBSE) in Focus: Stock Moves 5.6% Higher
by Zacks Equity Research
NeuBase (NBSE) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Utragenyx Shares Soar Above 60% YTD on Pipeline Developments
by Zacks Equity Research
Ultragenyx's (RARE) shares rise more than 60% year to date on various positive pipeline developments.
Mustang Bio (MBIO) Jumps: Stock Rises 8.2%
by Zacks Equity Research
Mustang Bio (MBIO) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Immunic Gets FDA Allowance for Phase II Coronavirus Study
by Zacks Equity Research
Immunic (IMUX) gets a FDA allowance to begin a phase II study on its DHODH inhibitor IMU-838 for addressing COVID-19 in the United States. Top-line results on the same are awaited later this year.
Nabriva Therapeutics (NBRV) Catches Eye: Stock Jumps 11.4%
by Zacks Equity Research
Nabriva Therapeutics (NBRV) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.
Arcus Biosciences (RCUS) Catches Eye: Stock Jumps 5.4%
by Zacks Equity Research
Arcus Biosciences (RCUS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Alexion (ALXN) Catches Eye: Stock Jumps 7.8%
by Zacks Equity Research
Alexion (ALXN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Regeneron Pharmaceuticals (REGN) Jumps: Stock Rises 6.3%
by Zacks Equity Research
Regeneron Pharmaceuticals (REGN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
ACADIA to Merge Two Phase III Studies on Nuplazid for MDD
by Zacks.com
ACADIA (ACAD) to club two late-stage studies on Nuplazid into a single evaluation program for the adjunctive treatment of MDD. Top-line results from the same are expected in Q3.
Intercept Down on Postponement of AdCom Meet for NASH Drug
by Zacks.com
The FDA defers advisory committee meeting date pertaining to Intercept's (ICPT) NDA for obeticholic acid to treat liver fibrosis due to nonalcoholic steatohepatitis.
Why Akcea (AKCA) Stock Might be a Great Pick
by Zacks Equity Research
Akcea (AKCA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Akcea Therapeutics (AKCA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Akcea Therapeutics (AKCA) delivered earnings and revenue surprises of 6.67% and -70.23%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Akcea Therapeutics (AKCA) Q1 Earnings Expected to Decline
by Zacks Equity Research
Akcea Therapeutics (AKCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for March 25th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
New Strong Sell Stocks for March 18th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for March 9th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Pfizer's Cardiomyopathy Drug Vyndaqel Gets Approval in Europe
by Zacks Equity Research
Pfizer's (PFE) Vyndaqel gets approval in Europe and becomes the first therapy approved to treat ATTR-CM in the continent.